Multicenter Retrospective Study Will Analyze Lesions Using AI-Powered CCTA Analysis, Advancing Elucid’s CCTA 3.0 Vision for Personalized CAD Treatment BOSTON – July 9, 2026 – Elucid, an innovator in AI-powered coronary CT angiography (CCTA) analysis, today announced...

Company will showcase highly accurate and reproducible plaque analysis as well as biointegrated FFR-CT data1 to identify lesion-level risk and enable patient-level impact BOSTON – July 6, 2026 – Elucid, an innovator in AI-powered coronary CT angiography (CCTA)...

Landmark 10th Annual Awards Program Recognizes the Most Innovative Digital Health and Medical Technology Solutions Worldwide BOSTON – May 7, 2026 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to...

New functionality puts the power of lesion-specific plaque analysis directly into the physician’s hands, giving deeper insight into coronary and carotid artery disease BOSTON – April 15, 2026 – Elucid announced today the commercial availability of a new Lesion...

Effective January 1, 2026, its Plaque-IQ™ coronary plaque analysis has received a new Category I Current Procedural Terminology (CPT®) designation, alongside increasingly widespread coverage and reimbursement from both public and private payors. Together, these developments underscore the clinical value of coronary plaque analysis and establish favorable conditions for broader adoption of the technology.

Elucid has announced new Hospital Outpatient Prospective Payment (OPPS) and Physician Fee Schedule (PFS) decisions from the U.S. Centers for Medicare & Medicaid Services (CMS) that establish significant reimbursement for coronary plaque analysis using PlaqueIQ across care settings.

The first and only CT-based plaque analysis indicated for the carotid anatomy that can help physicians assess risk of rupture and ischemic stroke 1 BOSTON - October 29, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise...

BOSTON – August 11, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, announced that United Healthcare has updated its cardiac imaging guidelines...

Leaders in clinical, product innovation, and market access will provide guidance for PlaqueIQTM strategy BOSTON and SCCT ANNUAL MEETING, MONTREAL – July 17, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of...

New reimbursement recommendations support earlier, non-invasive identification of high-risk cardiovascular patients BOSTON – July 15, 2025 – Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive...